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ABSTRACT
Background. The 10-year overall survival with adjuvant
hepatic arterial infusion pump (HAIP) chemotherapy after
resection of colorectal liver metastases (CRLMs) was 61%
in clinical trials from Memorial Sloan Kettering Cancer
Center. A pilot study was performed to evaluate the safety
and feasibility of adjuvant HAIP chemotherapy in patients
with resectable CRLMs.
Study Design. A phase II study was performed in two
centers in The Netherlands. Patients with resectable CRLM
without extrahepatic disease were eligible. All patients
underwent complete resection and/or ablation of CRLMs
and pump implantation. Safety was determined by the
90-day HAIP-related postoperative complications from the
day of pump placement (Clavien–Dindo classification,
grade III or higher) and feasibility by the successful
administration of the first cycle of HAIP chemotherapy.
Results. A total of 20 patients, with a median age of
57 years (interquartile range [IQR] 51–64) were included.
Grade III or higher HAIP-related postoperative complica-
tions were found in two patients (10%), both of whom had
a reoperation (without laparotomy) to replace a pump with
a slow flow rate or to reposition a flipped pump. No arterial
bleeding, arterial dissection, arterial thrombosis, extrahep-
atic perfusion, pump pocket hematoma, or pump pocket
infections were found within 90 days after surgery. After a
median of 43 days (IQR 29–52) following surgery, all
patients received the first dose of HAIP chemotherapy,
which was completed uneventfully in all patients.
Conclusion. Pump implantation is safe, and administra-
tion of HAIP chemotherapy is feasible, in patients with
resectable CRLMs, after training of a dedicated multidis-
ciplinary team.
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Recurrent disease is reported in up to 70% of patients
after resection of colorectal liver metastases (CRLMs).1
Reported 5- and 10-year overall survival (OS) of CRLM
patients treated with resection and systemic chemotherapy
were 40% and 25%, respectively.1
The rationale of adjuvant hepatic arterial infusion pump
(HAIP) chemotherapy after resection of CRLM is that
initial recurrences involve the liver in half of the patients.
HAIP chemotherapy involves a subcutaneous surgically
implanted pump that delivers chemotherapy through a
catheter directly into the hepatic artery via the gastroduo-
denal artery (GDA). Arterial administration is preferred
because liver tumors mainly depend on arterial rather than
portal venous blood supply.2,3 Floxuridine (or FUDR) is
the preferred drug for HAIP chemotherapy. Due to its high
hepatic extraction rate, intratumoral exposure is up to
400-fold higher compared with systemic administration,
with little or no systemic toxicity.4 Two randomized con-
trolled trials (RCTs) performed in the 1990s demonstrated
superior OS of HAIP chemotherapy. Moreover, the 10-year
OS of patients who received adjuvant HAIP chemotherapy
in several phase II trials after 2003 was 61%.5,6
Regardless of these impressive results, HAIP
chemotherapy is not commonly used outside of Memorial
Sloan Kettering Cancer Center (MSKCC). One of the
barriers is that floxuridine is not registered in the European
Union (EU). Moreover, HAIP chemotherapy requires
comprehensive training of and commitment from a multi-
disciplinary team.
Previous studies demonstrated both safety and feasibil-
ity concerns due to its complexity, requiring both technical
knowledge and practical skills.7–9 However, a previous
study of 544 patients demonstrated that an experienced
team was associated with less pump-related complications.
The pump failure rate was only 5% in the first 6 months
after implantation.2 HAIP-related postoperative complica-
tions include pump flow-rate abnormalities, pump
dislocation, arterial bleeding, arterial dissection, arterial
thrombosis, extrahepatic perfusion, pump pocket hema-
toma, and pump pocket infections.8
The aim of this study was to determine the safety and
feasibility of adjuvant HAIP chemotherapy after resection
of CRLMs in two centers in The Netherlands.
METHODS
Study Design
A phase II, multicenter, single-arm, safety and feasi-
bility study was conducted from February 2018 to February
2019 at the Erasmus MC Cancer Institute (Rotterdam) and
The Netherlands Cancer Institute (Amsterdam) in The
Netherlands. The Institutional Review Board approved the
study protocol (MEC-2017-282). The study was registered
in the Netherlands Trial Register (number 6917).
Patients
All patients with histologically confirmed colorectal
cancer and resectable CRLM without extrahepatic disease
(EHD) were evaluated for inclusion. EHD was defined as
any disease outside the liver prior to or at time of diagnosis
of CRLM. Patients with EHD found at surgery were
excluded. Patients were also excluded if positioning of a
catheter for HAIP chemotherapy was not feasible based on
a preoperative arterial computed tomography (CT) scan,
prior hepatic radiation or resection, CRLM requiring two-
staged resection, liver-first approach, and diagnosis of
another malignancy. Positioning of a catheter was not
considered feasible if the GDA had no connecting branch
to the left or right liver (e.g. in a patient with a completely
replaced right and left hepatic artery).
Training
The initial eight implantations (four in each center) were
performed under the supervision of surgeons from MSKCC
(MD and TK), who both have over 10-years of experience
in pump implantations (i.e. a total of more than 200
implantations each). The multidisciplinary teams of both
participating centers visited MSKCC for a 2-day workshop.
Additional training involved detailed protocols and video
material of the surgical pump implantation. A PhD student
attended all implantations, supervised pump refills, and
provided hands-on workshops for nurses and staff
members.
Surgical Procedure
A dedicated team of two surgeons in each center per-
formed all implantations. Surgical resection of CRLMs by
laparotomy, with or without resection of the primary
tumor, was combined with implantation of the HAI pump
with a constant non-programmable flow rate (Tricumed
IP2000 V). This pump has similar specifications as the
pump used in MSKCC (Codman 3000), with the main
difference being that the reservoir of the Tricumed pump is
pressurized by butane rather than Freon, which is not
allowed in the EU due to environmental laws. Treatment of
the CRLMs involved complete resection and/or open
ablation. In case of a simultaneous resection of the primary
tumor, liver resection with pump implantation was per-
formed first, followed by resection of the primary tumor to
prevent contamination of the pump. Prior to pump
implantation, a function test was performed to check the
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adequate operation of the pump. A cholecystectomy was
performed to avoid cholecystitis as a result of intra-arterial
chemotherapy through the cystic artery.10 The pump
pocket was created at the left-lower quadrant of the
abdominal wall, or in the right-lower quadrant in patients
with a colostomy. The pocket cavity was created three-
quarters caudal to the incision to ensure easy access of the
pump septum for percutaneous refills.
The entire GDA, as well as the proximal proper hepatic
artery, were mobilized and dissected circumferentially
from their attachments to facilitate insertion of the catheter
and to avoid inadvertent perfusion of the pancreas, stom-
ach, or duodenum. The distal GDA was ligated with a non-
absorbable tie and a transversal arteriotomy was performed
followed by insertion of the catheter. The catheter was
positioned just at the origin of the GDA. Positioning of the
catheter with the tip in the hepatic artery may cause tur-
bulence and the risk of thrombosis, while positioning the
catheter too far from the hepatic artery may cause pooling
of floxuridine in the GDA, with a risk of erosion, a pseu-
doaneurysm, and hemorrhage. A metal connector was used
to connect a commercially available (B. Braun Celsite)
intra-arterial catheter (distal catheter) with the Tricumed
catheter that comes with the pump (Tricumed Catheter
1000). This connection was secured with two non-ab-
sorbable ties. The distal catheter has several beads (i.e.
local thickening of the catheter wall), which were used to
secure the catheter with non-absorbable ties in the GDA.
Perfusion of both lobes of the liver and lack of extrahepatic
perfusion was confirmed by an intraoperative bolus injec-
tion of methylene blue. After the perfusion test, the catheter
was flushed with heparinized saline, and the wounds were
closed. Any replaced and accessory hepatic arteries were
ligated, provided that a patent GDA connected with at least
one hepatic artery was present. Intrahepatic shunts will
typically reassure that the catheter perfuses all liver seg-
ments, which was confirmed intraoperatively, and during
follow-up with postoperative scintigraphy.
Postoperative Procedures
Prior to the start of HAIP chemotherapy, a postoperative
technetium-99-labeled macroaggregated albumin (Tc-99m
MAA) scintigraphy was performed to again confirm the
absence of extrahepatic perfusion. In case of extrahepatic
perfusion, patients were evaluated angiographically and
branches were embolized with re-testing prior to the start
of treatment.
Chemotherapeutic Regimen
HAIP chemotherapy was initiated 4–12 weeks after
surgery depending on the patients’ condition and liver
function. The pump was refilled with a heparinized saline
solution (35,000 IE in 35 mL NaCl 0.9%) every 2 weeks
until the start of HAIP chemotherapy to prevent thrombosis
of the catheter. All patients were scheduled for six cycles
of 4 weeks of HAIP chemotherapy with floxuridine. Each
cycle comprised 2 weeks of HAIP chemotherapy followed
by a 2-week rest period during which the pump was filled
with the heparinized saline solution. Floxuridine was
administered based on the MSKCC regimen (0.12 mg/
kg/day).11,12 If the actual weight was more than 25% above
the ideal weight, the dose of floxuridine was calculated
using the average of the actual and ideal weight. Flox-
uridine was administered in a solution of 35,000 IE heparin
and 25 mg dexamethasone in NaCl 0.9% with a total
volume of 35 ml. A prophylactic dose of 20 mg of proton
pump inhibitors was administered daily during HAIP
chemotherapy. No adjuvant systemic chemotherapy was
administered since this is not the standard of care in The
Netherlands.
Outcomes
Safety was determined by the percentage of postopera-
tive complications (Clavien–Dindo classification grade III
or higher) within 90 days after surgery related to HAI
pump placement. The feasibility was defined as the per-
centage of patients receiving at least one cycle of adjuvant
HAIP chemotherapy after resection of CRLMs.
Definitions and Statistical Analysis
Demographic and clinicopathological characteristics
were presented as medians with interquartile ranges
(IQRs), and as means with ranges for continuous variables
and proportions for categorical variables. CRLMs that were
detected within 3 months of resection of the primary tumor
were considered synchronous. Any chemotherapy admin-
istered within 3 months prior to resection was considered
as preoperative chemotherapy. A positive resection margin
(R1) was defined as tumor cells present at the resection
margin, and major liver resection was defined as complete
resection of three or more segments. All analyses were
performed using SPSS version 24 (IBM Corporation,
Armonk, NY, USA).
RESULTS
A total of 22 patients were included in two centers
(Erasmus MC Cancer Institute and The Netherlands Cancer
Institute, The Netherlands) from February 2018 until
February 2019. Two patients were excluded during sur-
gery; one patient had unresectable CRLMs found during
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intraoperative ultrasonography, and one patient was
excluded due to an occult peritoneal lesion that was found
during surgery and confirmed by frozen section biopsy. No
patients were excluded due to unexpected abnormal hepatic
artery anatomy. A total of 20 patients were eligible.
Baseline Characteristics
Baseline characteristics of 20 patients who were eligible
for surgical treatment and pump implantation are shown in
Table 1. Median age was 57 years (IQR 51–64), and the
majority of patients were male (n = 12, 60%). Most
patients had left-sided colorectal cancer (n = 11, 55%),
followed by rectal (n = 6, 30%) and right-sided colorectal
cancer (n = 3, 15%). About half of the patients had syn-
chronous CRLMs (n = 11, 55%).
Surgical Aspects
Surgical aspects are summarized in Table 2. Preopera-
tive chemotherapy was administered in seven patients
(35%). In four patients (20%), the procedure was combined
with simultaneous resection of the primary tumor; in seven
patients (35%), ablation was combined with resection; and
in two patients (10%), only open ablation and pump
implantation were performed. A major liver resection was
performed in four patients (20%). The hepatic arterial
anatomy was abnormal in 10 patients (50%), requiring
ligation of accessory or replaced left and/or right hepatic
arteries. The pump was positioned in the left-lower quad-
rant of the abdomen in 18 patients (90%). The right-lower
abdomen was the preferred site in two patients (10%) due
to a prior colostomy in the left-lower quadrant. The median
hospital stay was 8 days (IQR 6–9). Postoperative Tch-
99m MAA scintigraphy showed no signs of extrahepatic
perfusion in all patients.
Postoperative Complications
Postoperative complications are summarized in Table 3.
No postoperative 90-day mortality was found. No arterial
bleeding, arterial dissection, arterial thrombosis, pump
pocket hematoma, or pump pocket infections were found
within the first 90 days after surgery. Five patients (25%)
had postoperative complications of grade III or higher.
Two patients (10%) had complications related to HAI
pump placement; the first patient required pump replace-
ment due to a decreased flow rate of the pump, and the
second patient had a flipped pump (upside down) requiring
reoperation. In both patients, reoperation involved a local
exploration of the pump pocket without a laparotomy, with
same-day discharge. Both patients recovered uneventful
and continued HAIP chemotherapy within 2 weeks.
Another three patients (15%) required re-interventions
due to complications unrelated to HAI pump implantation.
One patient required a re-laparotomy for biliary peritonitis
as a result of biliary leakage at the liver resection margin,
as well as a second re-laparotomy due to fascial dehis-
cence. A second patient was readmitted with an intra-
abdominal fluid collection that was treated with both per-
cutaneous drainage and intravenous antibiotics. The third
patient was readmitted for percutaneous drainage of an
intra-abdominal fluid collection with negative culture. All
three patients recovered uneventful.
Initiation of Hepatic Arterial Infusion Pump (HAIP)
Chemotherapy
The median period to administration of the first cycle of
HAIP chemotherapy was 43 days (IQR 29–52). Percuta-
neous access of the pump for the first cycle of HAIP
chemotherapy was performed without adverse events in all
patients. All patients uneventfully completed the first cycle
of HAIP chemotherapy, which was the primary endpoint
for feasibility.
DISCUSSION
This study demonstrated that HAI pump implantation
and administration of adjuvant HAIP chemotherapy in
patients with resectable CRLMs is safe and feasible in The
Netherlands. Safety was demonstrated as two patients
(10%) developed HAIP-related postoperative complica-
tions that were resolved with a reoperation to replace or
reposition the subcutaneous pump. Feasibility was
demonstrated because all patients started HAIP
chemotherapy within 6 weeks after surgery.
As a result of the pump with a decreased flow rate, the
pre-implantation pump performance test procedure was
adapted. The pump flow rate is temperature-dependent,
reaching optimal flow rates at body temperature. The new
pump performance test included continuous heating of the
pump to 37 C within an ex vivo heater, allowing precise
observation of pump flow rate mimicking in vivo condi-
tions. In order to minimize the risk of pump dislocation
(flipping within the pump pocket), all pockets were created
with minimal residual space in order to achieve a tight fit
with minimal risk of dislocation of the infusion pump in the
pocket. In obese patients (i.e. BMI[ 30) we prefer to
position the pump on the chest wall. The observed com-
plication rate seems acceptable compared with a large
retrospective study in which 544 patients who underwent
pump implantation for CRLMs were evaluated.8 Pump-
related complications were reported in 120 patients (22%)
and were classified as related to the hepatic arterial system
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(n = 62, 51%), the catheter (n = 33, 26%), the pump-
pocket (n = 19, 16%), or the pump (n = 6, 5%). Technical
complications could be salvaged in 54 patients (45%). A
higher rate of complications was found with surgeons who
performed less than 25 implantations (31% vs. 19%;
p\ 0.001). Other perioperative factors were comparable
with our study: mean operative time (260 min vs. 241 min
in our study), mean blood loss (490 mL vs. 724 mL in our
study), and length of hospital stay (8 days vs. 9 days in our
study). However, long-term follow-up is needed for com-
plete comparison of our results with this study.
Our multidisciplinary approach with extensive training
and proctoring by MSKCC was essential for the safety and
feasibility of setting up an HAIP chemotherapy program. In
a previous RCT on hepatic arterial infusion (HAI)
chemotherapy, lack of training and experience appeared to
be the major factor for the failure of safety and feasibility.7
Lorenz et al. compared resection of CRLMs combined with
adjuvant HAI of 5-fluorouracil, with resection of CRLM
alone. The trial was prematurely terminated after interim
analysis for futility. At the time of interim analysis, a total
of 113 patients were randomized into each group. Eight
patients (7%) within the HAI group died within 30 days
after surgery; four deaths were related to HAI chemother-
apy toxicity, three were related to catheter-related bleeding,
and one was related to to angiography-induced shock. In
the control group, three patients (3%) died within 30 days.
High rates of dropouts, i.e. patients who did not receive the
assigned treatment, were reported in both groups, with
various reasons: 24 patients (21%) assigned to HAI ? re-
section (no catheter implanted [n = 7], CRLM not resected
[n = 6], malperfusion [n = 5], refusal of patient [n = 2],
port complications [n = 2], liver cirrhosis [n = 1], and
postoperative ileus [n = 1]), and 13 patients (12%) assigned
to resection alone (CRLM not resected [n = 10] and
residual disease after resection [n = 3]). Explanations that
could have accounted for the failure of this trial included
participation of 26 centers, with each center performing
only approximately one intra-arterial catheter placement
per year; the use of a port with a catheter in the flow of the
TABLE 1 Baseline characteristics
Age
(years)
Sex ASA
score
BMI
(kg/m2)
Location
CRC
T-
stage
CRC
Nodal
status
Synchronous/
metachronous
DFI
(months)
No. of
CRLMs
Size of the
largest
CRLM (cm)
CEA
(lg/L)
Median
(IQR) or
n (%)
57
(51–64)
Male:
12 (60)
2
(1–2)
27
(24–27)
Right: 3
(15)
3
(3–4)
N0: 6
(30)
Syn: 11 (55) 1 (0–13) 2 (1–5) 2.3 (0.8–7.1) 6
(3–26)
Case 1 58 Female 3 27 Rectum 3 0 Metachronous 6 1 6.7 23
Case 2 64 Male 2 34 Left 3 2 Metachronous 41 3 2.4 6
Case 3 52 Female 2 29 Left 3 1 Metachronous 13 1 2.8 5
Case 4 64 Male 3 24 Left 3 1 Metachronous 13 1 1.8 5
Case 5 75 Female 2 26 Left 3 0 Synchronous 0 1 2.2 8
Case 6 67 Male 1 24 Left 4 0 Synchronous 0 2 4.8 34
Case 7 50 Female 1 24 Left 3 0 Synchronous 2 2 2.0 63
Case 8 54 Male 3 24 Right 4 2 Metachronous 28 2 2.3 27
Case 9 68 Male 2 24 Right 4 2 Synchronous 0 5 1.2 40
Case 10 58 Male 2 25 Left 3 1 Synchronous 0 5 7.1 2
Case 11 57 Female 2 25 Left 4 2 Metachronous 15 2 4.8 1
Case 12 66 Male 3 23 Left 4 1 Synchronous 0 4 4.2 24
Case 13 51 Female 1 27 Rectum 3 1 Metachronous 2 5 1.3 3.
Case 14 42 Female 1 23 Left 3 0 Metachronous 4 13 1.5 3
Case 15 54 Female 1 25 Right 3 1 Synchronous 0 3 2.5 19
Case 16 61 Male 2 25 Left 3 1 Synchronous 0 2 1.6 3
Case 17 54 Male 2 28 Rectum 3 1 Synchronous 0 7 52 880
Case 18 43 Male 1 25 Rectum 2 1 Synchronous 0 12 0.8 4
Case 19 57 Male 1 24 Rectum 3 0 Metachronous 12 2 2.2 6
Case 20 46 Male 2 24 Rectum 2 1 Synchronous 0 1 1.0 3
ASA American Society of Anesthesiologists, BMI body mass index, CEA carcinoembryonic antigen, CRC colorectal cancer, CRLM colorectal
liver metastasis, DFI disease-free interval, IQR interquartile range, N0 node-negative, Syn synchronous, T-stage CRC tumor-stage colorectal
cancer
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hepatic artery, resulting in a high rate of technical failures
(e.g. hepatic arterial thrombosis); and the use of intra-ar-
terial 5-fluorouracil, which is not only less effective (lower
dose due to a smaller first-pass effect) but also has a much
higher systemic exposure compared with floxuridine.4
Several studies, including an RCT, demonstrated supe-
rior survival of HAIP chemotherapy compared with
systemic chemotherapy alone in patients with
resectable CRLM.5,6,13,14 A phase III RCT for adjuvant
HAIP chemotherapy found an improvement in 2-year
survival (86% vs. 72%; p = 0.03).13 Long-term follow-up
of 287 patients receiving adjuvant HAIP chemotherapy in
four prospective trials at MSKCC demonstrated a 10-year
OS of 61%.5 A recent propensity scored analysis demon-
strated an OS benefit of 23 months of adjuvant HAIP
chemotherapy compared with systemic chemotherapy
alone (67 months vs. 44 months; p\ 0.001).14 The OS
without HAIP was similar with other large cohorts outside
MSKCC.15 The difference remained at propensity score
analysis, with an adjusted hazard ratio of 0.67 (95% con-
fidence interval 0.59–0.76; p\ 0.001).
Implementation of HAIP chemotherapy beyond
MSKCC is currently limited to a few centers around the
world (e.g. University Hospital Zurich, Zurich, Switzer-
land; University of Pittsburgh Medical Center, Pittsburgh,
PA, USA; and Washington University School of Medicine,
St. Louis, MO, USA). Several explanations have been
suggested that could account for this. The historical per-
spective may be partly responsible. The first trials on HAIP
chemotherapy date from the 1990s, a decade in which new
promising agents for systemic chemotherapy such as
irinotecan and oxaliplatin were introduced. Administration
of intravenous drugs was simple compared with the
implementation of HAIP chemotherapy, which required
new skills and close collaboration within multidisciplinary
teams. Modern systemic chemotherapy results in superior
survival in selected patients with stage IV CRC.16,17 In the
TABLE 3 Postoperative complications within 90 days of surgery
Number Grade III or higher
(Clavien–Dindo)
HAI
pump-
related
Time to
event (days)
Requiring
readmission
Requiring
surgery
Specified
Total
(%)
5 (25) 2 (10) 4 (20) 3 (15)
Case 1 –
Case 2 IIIb Yes 42 Yes Yes Pump replacement due to slow flow rate
Case 3 IIIb Yes 41 Yes Yes Flipped pump
Case 4 –
Case 5 –
Case 6 IVa No 4 No Yes (29) 1. Biliary peritonitis due to biliary leakage at the
liver resection margin
2. Threatening abdominal fascial dehiscence
Case 7 –
Case 8 –
Case 9 –
Case 10 IIIa No 13 Yes No Percutaneous drainage of sterile abdominal fluid
collection
Case 11 IIIa No 9 Yes No Spontaneous bacterial peritonitis requiring
antibiotics and percutaneous drainage
Case 12 –
Case 13 –
Case 14 –
Case 15 –
Case 16 –
Case 17 –
Case 18 –
Case 19 –
Case 20 –
HAI hepatic arterial infusion
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subgroup of patients with resectable CRLM, no OS benefit
was found (p = 0.30) in a phase III RCT, although pro-
gression-free survival was superior in the per protocol
analysis (p = 0.035).18 Despite these results, the recurrence
rate was still about 70%. This disappointing high per-
centage of recurrent disease after curative resection of
CRLMs and perioperative systemic chemotherapy has
renewed interest in adjuvant HAIP chemotherapy.
Second, regulatory factors have also opposed imple-
mentation of HAIP chemotherapy outside the US.
Floxuridine was first registered by the US FDA in 1971;
however, in the EU, floxuridine cannot be used outside
clinical trials since it is not registered. Others have resorted
to 5-fluorouracil or oxaliplatin instead of floxuridine. A
previous trial on intermittent infusion of 5-fluorouracil
through a mediport in the hepatic artery was terminated
prematurely, mainly due to a high rate of 5-fluorouracil-
related complications.7 However, the hallmark of HAIP
chemotherapy is the 95% first-pass effect of floxuridine in
the liver that allows for a very high dosage with continuous
infusion without systemic toxicity.
No infusion pump with the intended use of intra-arterial
chemotherapy is currently registered in the EU. The Tri-
cumed IP2000 V infusion pump is CE marked and has
been used for many years in patients with spasticity and
chronic pain. Both registration of floxuridine, and an
infusion pump for HAIP chemotherapy, are essential steps
for implementation of this treatment in the EU. The sub-
cutaneous pump is a key component of the intra-arterial
chemotherapy because floxuridine has a half-life of only
10 min.4 A percutaneous approach for the delivery of intra-
arterial chemotherapy has been investigated by the Gustave
Roussy Hospital in Paris (France).19 Goe´re´ et al. adminis-
tered intra-arterial oxaliplatin using a percutaneous catheter
in the hepatic artery. With the percutaneous approach, a
catheter remains positioned in the flow of the hepatic
artery, with a higher risk of hepatic artery thrombosis.
Therefore, the percutaneous approach is not suitable for
prolonged administration. The pump has an intra-arterial
catheter in the GDA, outside the hepatic arterial flow and
therefore less likely to cause thrombosis. The pump can
stay in for many years for the treatment of disease recur-
rence in the liver. Furthermore, the surgical approach
allows complete circumferential dissection of the artery,
which is important to avoid complications of extrahepatic
perfusion of floxuridine. The potential effects of extra-
hepatic perfusion of floxuridine are more severe than the
effects of extrahepatic perfusion of oxaliplatin due to the
high dose of floxuridine administered compared with
oxaliplatin, provided by its high first-pass effect.
CONCLUSIONS
This is the first study prospectively reporting early
safety and feasibility results on adjuvant HAIP
chemotherapy in patients with resectable CRLM. Some
fundamental elements have been considered in the design
of our program, including thorough training on all safety
and technical aspects, selection of appropriate materials,
and careful selection of patients and participating centers.
The number of participating centers for the safety and
feasibility study was only two, to guarantee adequate
training and experience. All future implantations will be
performed by a team of two experienced surgeons, and new
surgeons will only be allowed to perform implantations
after thorough training to sustain knowledge and skills.
After confirming safety and feasibility, we proceeded
with a multicenter, phase III RCT (the PUMP trial) to study
the effectiveness of adjuvant HAIP chemotherapy in
patients with resectable CRLMs (www.trialregister.nl:
NTR7493).20
This study showed that starting an HAIP chemotherapy
program can be safe and feasible after adequate training
and proctoring of a multidisciplinary team.
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